| pubmed-article:8088980 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8088980 | lifeskim:mentions | umls-concept:C0032285 | lld:lifeskim |
| pubmed-article:8088980 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8088980 | lifeskim:mentions | umls-concept:C0007562 | lld:lifeskim |
| pubmed-article:8088980 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:8088980 | lifeskim:mentions | umls-concept:C0991537 | lld:lifeskim |
| pubmed-article:8088980 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8088980 | pubmed:dateCreated | 1994-10-20 | lld:pubmed |
| pubmed-article:8088980 | pubmed:abstractText | For children with acute respiratory infections in hospital, it is desirable to transfer from parenteral to oral therapy at the earliest opportunity. The introduction of a pediatric suspension of cefuroxime axetil provides a continuous course of one antibiotic with transition from injectable to oral therapy. This open study was designed to investigate the efficacy of cefuroxime in pediatric patients aged 3 months to 5 years with community-acquired pneumonia. Children had evidence of lobar pneumonia on chest X-ray, a white blood cell count of > 15,000/mm3 and a rectal temperature of > or = 38.5 degrees C on enrollment. Cefuroxime was given by i.v. injection at 75 mg/kg per day in three divided doses for 48-72 h followed by oral cefuroxime suspension at 30 mg/kg per day in two divided doses. Of 84 evaluable patients 82 (97.6%) were cured or improved post-treatment, and of 74 evaluable children who returned for follow-up assessment 73 (98.6%) remained well. Oral therapy with twice daily cefuroxime axetil suspension following 2-3 days of i.v. cefuroxime administration was confirmed as effective and safe treatment for lobar pneumonia in children under 5 years of age. | lld:pubmed |
| pubmed-article:8088980 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8088980 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8088980 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8088980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8088980 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8088980 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8088980 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:8088980 | pubmed:issn | 0021-2180 | lld:pubmed |
| pubmed-article:8088980 | pubmed:author | pubmed-author:EngelhardDD | lld:pubmed |
| pubmed-article:8088980 | pubmed:author | pubmed-author:DaganRR | lld:pubmed |
| pubmed-article:8088980 | pubmed:author | pubmed-author:ShalitII | lld:pubmed |
| pubmed-article:8088980 | pubmed:author | pubmed-author:EphrosMM | lld:pubmed |
| pubmed-article:8088980 | pubmed:author | pubmed-author:CuninghamKK | lld:pubmed |
| pubmed-article:8088980 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8088980 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:8088980 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8088980 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8088980 | pubmed:pagination | 684-9 | lld:pubmed |
| pubmed-article:8088980 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:meshHeading | pubmed-meshheading:8088980-... | lld:pubmed |
| pubmed-article:8088980 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8088980 | pubmed:articleTitle | Cefuroxime efficacy in pneumonia: sequential short-course i.v./oral suspension therapy. | lld:pubmed |
| pubmed-article:8088980 | pubmed:affiliation | Department of Pediatrics, Tel Aviv Sourasky Medical Center (Ichilov Hospital), Israel. | lld:pubmed |
| pubmed-article:8088980 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8088980 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8088980 | pubmed:publicationType | Multicenter Study | lld:pubmed |
